vs 8.4AE4.8 days no readmission, p¼0.003), there was no significant relationship after adjusting for other factors (20.6% 0-6 days vs 19.5% 10+ days, adjusted OR 1.03, 95% 0.79-1.35, Figure) . A subset analysis examining only surgery-related readmissions demonstrated similar findings.
INTRODUCTION AND OBJECTIVES:
To survey long-term outcomes of dialysis patients with urothelial cancers undergone complete urinary tract exenteration (bilateral nephroureterectomy and cystectomy) METHODS: We retrospectively reviewed our patients with urinary tract urothelial cancer. A total of 42 dialysis patients who received complete urinary tract exenteration were enrolloed in our study. Seventeen patients received one-stage complete urinary tract exenteration and twenty-five patients who had multi-stage surgery. We review the demographic, clinical, surgical, and pathological data to determine what clinical and pathologic variables affected the survival between two groups. RESULTS: Baseline demographics were comparable in both groups. There was no significant difference in age, American Society of Anesthesiologists class, Charlson index or body mass index between the 2 groups. There were no statistically different in terms of estimated blood loss (1280 vs. 1440 ml) and total hospital stay (31 vs. 21 days). In comparsion to the multi-stage surgery, one-stage surgery was associated with a high complication rate (58.8% (10/17) vs. 8%( 2/25) ). Twenty two patients were still alive at the end of the study and 20 patients had died. The median survival after confirmation of complete urinary tract exenteration status was 27.5 months. The overall survival was not different between two groups. Charlson comorbidity index was a mandatory indicator to predict long term survival outcome.
CONCLUSIONS: In dialysis patients with urothelial cancers undergone complete urinary tract exenteration, one stage complete urinary tract exenteration had high periopearative complication rate. Charlson comorbidity index was a mandatory indicator to predict long term survival outcome. RESULTS: While the overall trend of imaging use remained essentially unchanged over the study period, there was a significant decrease in the proportion of patients who received conventional imaging modalities (MRI and CT; P < .05) and a significant increase in the proportion of patients receiving the more advanced imaging modality (PET/CT; P < .0001). On multivariable analysis, receipt of PET/CT was significantly higher in female patients, Non-Hispanics, residents in West Census region, patients with higher grade tumors, those diagnosed with advanced stage disease, hydronephrosis, and those that received radical cystectomy and chemotherapy. In the cost analysis, the estimated national excess medical spending for advanced imaging was $6.1 million.
CONCLUSIONS: The sharp increase of advanced imaging (PET/CT) and substantial costs associated with this rapid adoption as we have documented suggests that further efforts should be made to evaluate the clinical and economic benefits of PET/CT imaging and to elucidate its appropriateness of use among bladder cancer patients. Vol. 197, No. 4S, Supplement, Friday, May 12, 2017 THE JOURNAL OF UROLOGY â e251
